Sign In
Buy CAPR
$25.33
-0.680 (-2.61%)
At Close: Jun 10, 2026
Martin Shkreli's Biotech Short Position Is Blowing Up As Stock Soars 440%: Momentum Score Spikes
04:31am, Monday, 08'th Dec 2025
Investor Martin Shkreli's big biotech short position is blowing up after the stock's monumental rally over the past week.
Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel
08:21am, Sunday, 07'th Dec 2025
Capricor Therapeutics maintains a "Hold" rating despite positive phase 3 HOPE-3 results for Deramiocel in DMD cardiomyopathy. HOPE-3 met both primary [PUL v2.0] and key secondary [LVEF] endpoints, ali
Biotech Stocks To Add to Your Watchlist – December 5th
02:04am, Sunday, 07'th Dec 2025
Danaher, Moderna, and Capricor Therapeutics are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that develop medicines, b
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript
01:18am, Saturday, 06'th Dec 2025
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript
CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know
11:36am, Friday, 05'th Dec 2025
Capricor Therapeutics stock soars after meeting key goals with statistical significance in a phase III study of deramiocel for Duchenne cardiomyopathy.
Caprock Announces Proposed Private Placement
04:15pm, Thursday, 04'th Dec 2025
Toronto, Ontario--(Newsfile Corp. - December 4, 2025) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
04:01pm, Thursday, 04'th Dec 2025
SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the comm
Martin Shkreli touts QCLS stock as a long idea after a “bad call” on CAPR
12:05pm, Thursday, 04'th Dec 2025
Q/C Technologies In (NASDAQ: QCLS) soared another 60% on Thursday morning after former pharmaceutical executive Martin Shkreli touted the company as a “long idea”. According to him, the photonic c
Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say
02:21pm, Wednesday, 03'rd Dec 2025
Capricor Therapeutics, Inc. (NASDAQ: CAPR) stock soared on Wednesday after the company announced positive topline data from the Phase 3 HOPE-3 trial for its lead cell therapy candidate, deramiocel.
Biotech Stock Up Over 400% After Late-Stage Breakthrough
10:36am, Wednesday, 03'rd Dec 2025
Capricor Therapeutics Inc (NASDAQ:CAPR) is one of the best stocks on Wall Street today, up 263% to trade at $23.09, after the biotech company's cell therapy for a heart condition related to Duchenne's
Capricor Therapeutics Duchenne Treatment Shows Strong Heart And Muscle Results In Trial
09:23am, Wednesday, 03'rd Dec 2025
Capricor Therapeutics Inc. (NASDAQ: CAPR) stock is rallying on Wednesday.
Capricor's muscle disorder cell therapy succeeds in late-stage study
07:44am, Wednesday, 03'rd Dec 2025
Capricor Therapeutics said on Wednesday its cell therapy for a heart condition related to a rare muscular disorder met the main goal of a late-stage study, months after U.S. regulators rejected its in
Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
07:20am, Wednesday, 03'rd Dec 2025
Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2. 0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (
Martin Shkreli Takes Aim At Capricor — Stock Sinks
01:49pm, Monday, 24'th Nov 2025
Shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) plummeted Monday due to a short call from controversial former pharmaceutical executive Martin Shkreli.
Traders Buy High Volume of Capricor Therapeutics Put Options (NASDAQ:CAPR)
01:07am, Wednesday, 12'th Nov 2025
Capricor Therapeutics, Inc. (NASDAQ: CAPR - Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders acquired 17,427 put options on the stock. This is an increase of 2
